| Literature DB >> 23589677 |
Yusuke Shimizu1, Hiroshi Toshida, Rio Honda, Asaki Matsui, Toshihiko Ohta, Yousuke Asada, Akira Murakami.
Abstract
PURPOSE: To investigate the microbial isolates from patients with ocular infections and the trend in the emergence of levofloxacin-resistant strains over the past four years from 2006 to 2009 retrospectively. PATIENTS AND METHODS: The subjects were 242 patients with ocular infections or traumas treated in our hospital including outpatients, inpatients, and emergency room patients. Most of them needed urgent care presenting with eye complaints, traumas, or decreased vision. Clinical samples were obtained from discharges, corneal, conjunctival tissues or vitreous fluid or aqueous humor, and cultured. Items for assessment included the patient's age, the diagnosis, the prevalence of isolated bacteria, and the results of susceptibility tests for levofloxacin (LVFX) cefamezin (CEZ), gentamicin (GM) and vancomycin. This information was obtained from the patients' medical records.Entities:
Keywords: drug resistance; levofloxacin; minimum inhibitory concentration; ocular infections; vancomycin
Year: 2013 PMID: 23589677 PMCID: PMC3625025 DOI: 10.2147/OPTH.S43323
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Microbial isolates and the total numbers of each strain
| Infectious corneal ulcer | Corneal perforation | Orbital cellulitis | Endophthalmitis | Conjunctivitis | Dacryoadenitis | Blepharitis | Total | % | |
|---|---|---|---|---|---|---|---|---|---|
| CNS | 8 | 6 | 3 | 3 | 1 | 1 | 22 | 17.7% | |
| MRCNS | 5 | 4 | 1 | 3 | 4 | 17 | 13.7% | ||
| 3 | 2 | 1 | 4 | 2 | 2 | 14 | 11.3% | ||
| MRSA | 2 | 1 | 2 | 3 | 4 | 12 | 9.7% | ||
| 2 | 1 | 4 | 1 | 1 | 9 | 7.3% | |||
| 3 | 2 | 1 | 1 | 7 | 5.6% | ||||
| 1 | 1 | 1 | 1 | 4 | 3.2% | ||||
| Sub total | 21 | 12 | 10 | 15 | 15 | 10 | 2 | 85 | 68.5% |
| 7 | 1 | 2 | 2 | 12 | 9.7% | ||||
| 6 | 1 | 7 | 5.6% | ||||||
| 3 | 3 | 2.4% | |||||||
| 2 | 1 | 3 | 2.4% | ||||||
| 1 | 2 | 3 | 2.4% | ||||||
| 2 | 2 | 1.6% | |||||||
| 2 | 2 | 1.6% | |||||||
| 1 | 1 | 0.8% | |||||||
| 1 | 0.8% | ||||||||
| 1 | 1 | 0.8% | |||||||
| 1 | 1 | 0.8% | |||||||
| 1 | 1 | 0.8% | |||||||
| Sub total | 24 | 2 | 3 | 3 | 5 | 0 | 0 | 37 | 29.8% |
| Candida | 1 | 1 | 0.8% | ||||||
| Unknown | 1 | 1 | 0.8% | ||||||
| Sub total | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1.6% |
| Total | 45 (36.3%) | 15(12.1%) | 13 (10.5%) | 19(15.3%) | 20(16.1%) | 10(8.1%) | 2(1.6%) | 124 | 100.0% |
Notes: Data were raw total numbers of microorganism strains obtained by each disease. If the bacteria was obtained from different samples of one patient at the same time.
Abbreviations: CNS, coagulase negative Staphylococcus; MRCNS, methicillin-resistant CNS; MRSA, methicillin-resistant Staphylococcus aureus.
Levofloxacin resistant-bacterial isolates and rates
| Infectious corneal ulcer | Corneal perforation | Orbital cellulitis | Endophthalmitis | Conjunctivitis | Dacryoadenitis | Blepharitis | Total | |
|---|---|---|---|---|---|---|---|---|
| CNS | 0/8 | 6/6 | 0/3 | 1/3 | 1/1 | 0/1 | 8/22 (36.4%) | |
| MRCNS | 1/5 | 4/4 | 0/1 | 2/3 | 3/4 | 10/17(58.8%) | ||
| 0/3 | 0/2 | 0/1 | 0/4 | 0/2 | 0/1 | 0/14(0.0%) | ||
| MRSA | 2/2 | 0/1 | 2/2 | 3/3 | 4/4 | 11/12(91.7%) | ||
| 0/2 | 1/1 | 4/4 | 1/1 | 1/1 | 7/9 (77.8%) | |||
| 2/3 | 0/2 | 0/1 | 0/1 | 2/7 (28.6%) | ||||
| 0/1 | 0/1 | 0/1 | 0/1 | 0/0 (0.0%) | ||||
| Sub total | 3/21 (14.3%) | 10/12(83.3%) | 2/10(20.0%) | 6/15(40.0%) | 10/15(66.7%) | 6/10(60.0%) | 1/2(50.0%) | 38/85 (44.7%) |
| 0/7 | 0/1 | 1/2 | 0/2 | 1/12(8.3%) | ||||
| 0/6 | 0/1 | 0/7 (0.0%) | ||||||
| 0/3 | 0/3 (0.0%) | |||||||
| 0/2 | 0/1 | 0/3 (0.0%) | ||||||
| 0/1 | 0/2 | 0/3 (0.0%) | ||||||
| 0/2 | 0/2 (0.0%) | |||||||
| 0/2 | 0/2 (0.0%) | |||||||
| 1/1 | 1/1 (100.0%) | |||||||
| 0/1 | 0/1 (0.0%) | |||||||
| 0/1 | 0/1 (0.0%) | |||||||
| 0/1 (0.0%) | ||||||||
| 0/1 | 0/1 (0.0%) | |||||||
| Sub total | 1/24(4.2%) | 0/1 (0.0%) | 0/3 (0.0%) | 0/3 (0.0%) | 1/5 (20.0%) | 0/0 (0.0%) | 0/0 (0.0%) | 2/37 (5.4%) |
| Total | 4/45 (8.9%) | 10/15(66.7%) | 2/13 (15.4%) | 6/19(31.6%) | 11/20(55.0%) | 6/10(60.0%) | 1/2(50.0%) | 40/122(32.8%) |
The minimum inhibitory concentration
| LVFX | GM | CEZ | |
|---|---|---|---|
| Infectious corneal ulcer | 1.94 ± 2.16 | 5.14 ± 5.66 | 19.14 ± 14.93 |
| Corneal perforation | 5.93 ± 3.40 | 13.7 ± 5.45 | 15.67 ± 14.94 |
| Orbital cellulitis | 1.86 ± 2.24 | 4.33 ± 5.72 | 7.00 ± 12.25 |
| Endophthalmitis | 2.42 ± 2.68 | 5.50 ± 6.26 | 11.63 ± 14.20 |
| Conjunctivitis | 4.00 ± 3.14 | 7.54 ± 6.98 | 14.00 ± 14.83 |
| Dacryoadenitis | 3.63 ± 3.62 | 11.7 ± 6.74 | 17.00 ± 16.43 |
Notes: The MIC of LVFX, GM and CEZ for the clinical isolates from each ocular infectious disease. The mean MIC of LVFX and GM for isolates from patients with corneal perforation was significantly higher than that for isolates from the others (P < 0.01, respectively). Data were statistically analyzed by Tukey-Kramer method. Differences were considered significant at P < 0.05
P < 0.01.
Abbreviations: LVFX, levofloxacin; GM, gentamicin, CEZ, cefamezin; MIC, minimum inhibitory concentration.
The number and detection rate of ocular infectious diseases
| Total
| Male
| Female
| Differences between genders
| ||||
|---|---|---|---|---|---|---|---|
| Number | Detection rate (%) | Number | Detection rate (%) | Number | Detection rate (%) | ||
| Infectious corneal ulcer | 51/179 | 28.5% | 31/91 | 34.1% | 20/88 | 22.7% | |
| Corneal perforation | 15/25 | 60.0% | 15/20 | 75.0% | 0/5 | 0.0% | |
| Orbital cellulitis | 13/23 | 56.5% | 8/12 | 66.7% | 5/11 | 45.5% | |
| Endophthalmitis | 20/81 | 24.7% | 9/37 | 24.3% | 11/44 | 25.0% | |
| Conjunctivitis | 21/55 | 38.2% | 9/18 | 50.0% | 12/37 | 32.4% | |
| Dacryoadenitis | 10/22 | 45.5% | 4/6 | 66.7% | 6/16 | 37.5% | |
| Blepharitis | 2/4 | 50.0% | 2/3 | 66.7% | 0/1 | 0.0% | |
| others | 3/31 | 9.7% | 3/18 | 16.7% | 0/13 | 0.0% | |
| Total | 135/420 | 32.1% | 81/205 | 39.5% | 54/215 | 25.1% | |
Notes: The detection rate in this table was calculated by total number of examination. Data were statistically analyzed by 2 × 2 Chi square test. Differences between sexes were considered at P < 0.05
P < 0.01
P < 0.005.